GLP-1 (glucagon-like peptide-1) is a hormone the human gut releases after eating, and GLP-1 receptor agonist drugs are engineered to replicate its actionCITE:E1. The natural hormone promotes insulin secretion and suppresses appetite; drugs commonly called "GLP-1 weight-loss drugs" — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — are receptor agonists that mimic this effect rather than the hormone itselfCITE:E1.
GLP-1 receptor agonists slow gastric emptying and increase satiety, leading patients to eat less without deliberate restrictionCITE:E2. Some newer drugs, such as tirzepatide, act on both the GIP and GLP-1 receptors simultaneously, which produces a stronger weight-loss effect than single-receptor drugsCITE:E2.
Semaglutide's SELECT cardiovascular outcomes trial found a 20% reduction in major adverse cardiovascular events (MACE)CITE:E3. The trial enrolled 17,604 overweight or obese participants with a prior history of cardiovascular disease and recorded a hazard ratio of 0.80 for MACECITE:E3. Based on these results, the FDA added cardiovascular risk reduction to Wegovy's approved label in 2024, formally recognizing the heart benefit as a distinct clinical indication rather than a side effect of weight lossCITE:E3.
Novo Nordisk's semaglutide line and Eli Lilly's tirzepatide line are the two dominant players in today's marketCITE:E4. Novo Nordisk markets semaglutide as Ozempic for diabetes and Wegovy for obesity, while Eli Lilly markets tirzepatide as Mounjaro and ZepboundCITE:E4. Surging demand has made GLP-1 drugs one of the pharmaceutical industry's most important growth engines in recent yearsCITE:E4.
Eli Lilly's oral GLP-1 candidate, orforglipron, produced an average weight loss of about 12.4% over 72 weeks in a pivotal Phase 3 trialCITE:E5. Current GLP-1 drugs are administered mostly as weekly injections; an oral pill, if it reaches market, would lower manufacturing and distribution barriers and could expand access to more patientsCITE:E5.
GLP-1 drugs commonly cause gastrointestinal side effects such as nausea and diarrhea, and weight tends to return after treatment stopsCITE:E6. That rebound pattern means the drugs generally require long-term use, they carry a high cost, and long-term safety data along with evidence for additional uses — including kidney disease, sleep apnea, and addiction — are still being gathered in ongoing clinical workCITE:E6. GLP-1 drugs remain intended for use under medical supervisionCITE:E6.
| Metric | Value | Source |
|---|---|---|
| SELECT trial participants | 17,604 | CITE:E3 |
| MACE risk reduction (SELECT) | 20% (hazard ratio 0.80) | CITE:E3 |
| FDA cardiovascular-risk label update | 2024 | CITE:E3 |
| Oral GLP-1 (orforglipron) trial duration | 72 weeks | CITE:E5 |
| Oral GLP-1 (orforglipron) average weight loss | ~12.4% | CITE:E5 |
Taken together, these facts show that GLP-1's cardiovascular benefit is no longer a secondary observation but a result formally written into an FDA drug label following a 17,604-patient trial, while the same drug class's next competitive front — oral formulations — is already producing double-digit weight-loss results in late-stage testing, even as gastrointestinal side effects and post-treatment weight rebound remain unresolved parts of the pictureCITE:E3CITE:E5CITE:E6.
GLP-1 (glucagon-like peptide-1) is a hormone the human gut releases after eating, and GLP-1 receptor agonist drugs are engineered to replicate its actionCITE:E1…
GLP-1 receptor agonists slow gastric emptying and increase satiety, leading patients to eat less without deliberate restrictionCITE:E2.
Semaglutide's SELECT cardiovascular outcomes trial found a 20% reduction in major adverse cardiovascular events (MACE)CITE:E3.
Novo Nordisk's semaglutide line and Eli Lilly's tirzepatide line are the two dominant players in today's marketCITE:E4.
The detail that reframes this class of drugs is the SELECT trial's 20% MACE reduction across 17,604 patients, which pushed the FDA to add cardiovascular risk reduction to Wegovy's label in 2024 — that moves GLP-1 from a weight-loss category into a chronic cardiovascular-risk-management category with its own regulatory standing. At the same time, the market is still concentrated between two companies, Novo Nordisk and Eli Lilly, and the next competitive axis is delivery format rather than mechanism: Eli Lilly's oral orforglipron already shows about 12.4% weight loss over 72 weeks in Phase 3 testing. The metric worth watching next is whether that oral trial data holds up through full approval, since a pill removes the injection-based distribution constraints that have shaped access to this drug class so far.
Utility-scale solar has become one of the cheapest new power sources, with costs down roughly 90% since 2010, while 2024 deployment volume outpaced every other generation technology. Paired with record-low battery prices, solar-plus-storage is already powering an AI data center in Arizona — though it still falls short of full 24-hour dispatchable baseload.
2026 marks the European Union AI Act's real enforcement start: the AI Office gains fining power over general-purpose AI on August 2, while high-risk system deadlines are pushed to 2027 and 2028. California activates two new laws on January 1 covering frontier-developer safety disclosure and training-data transparency. The federal government moves the opposite direction, ordering a Justice Department task force to challenge state AI laws, naming California's SB 53 as a target.
China's EHang (億航) is the only eVTOL maker actually flying paying passengers today, holding a full Chinese type, production, and operating certificate set and delivering 221 aircraft in 2025. US rivals Joby and Archer remain in certification or pre-launch stages, while Germany's Lilium and Volocopter both went insolvent in 2024–2025, with Volocopter absorbed by a Chinese buyer.